JAK2-mutant Vascular Niche Contributes to JAK2 Clonal Expansion in Myeloproliferative Neoplasms

Overview

Journal Blood Cells Mol Dis

Specialty Hematology

Date 2016 Nov 20

PMID 27865175

Citations 18

Authors

Chi Hua Sarah Lin

Kenneth Kaushansky

Huichun Zhan

Affiliations

Soon will be listed here.

Abstract

The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of blood cells. The acquired mutation JAK2 plays a central role in these disorders. Mechanisms responsible for MPN HSPC expansion is not fully understood, limiting the effectiveness of current treatments. Endothelial cells (ECs) carrying the JAK2 mutation can be detected in patients with MPNs, suggesting that ECs are involved in the pathogenesis of MPNs. Here we report that JAK2-bearing primary murine ECs have increased cell proliferation and angiogenesis in vitro compared to JAK2 ECs. While there was no difference between JAK2 and JAK2 HSPC proliferation when co-cultured with JAK2 EC, the JAK2 HSPC displayed a relative growth advantage over the JAK2 HSPC when co-cultured on JAK2 EC. In addition, the thrombopoietin (TPO) receptor MPL is up regulated in JAK2 ECs and contributes to the maintenance/expansion of the JAK2 clone over JAK2 clone in vitro. Considering that ECs are an essential component of the hematopoietic niche and most HSPCs reside in the perivascular niche, our studies suggest that the JAK2-bearing ECs form an important component of the MPN vascular niche and contribute to mutant stem/progenitor cell expansion, likely through a critical role of the TPO/MPL signaling axis.

Citing Articles

New Markers of Disease Progression in Myelofibrosis.

Campanelli R, Massa M, Rosti V, Barosi G Cancers (Basel). 2021; 13(21).

PMID: 34771488 PMC: 8582535. DOI: 10.3390/cancers13215324.

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm.

Zhang H, Yeware A, Lee S, Zhan H Front Oncol. 2021; 11:753465.

PMID: 34765558 PMC: 8576565. DOI: 10.3389/fonc.2021.753465.

The possible role of mutated endothelial cells in myeloproliferative neoplasms.

Farina M, Russo D, Hoffman R Haematologica. 2021; 106(11):2813-2823.

PMID: 34320782 PMC: 8561279. DOI: 10.3324/haematol.2021.278499.

Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm.

Castiglione M, Zhang H, Kaushansky K, Zhan H Exp Hematol. 2021; 100:52-62.

PMID: 34153382 PMC: 9911310. DOI: 10.1016/j.exphem.2021.06.003.

JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.

Mazzeo C, Quan M, Wong H, Castiglione M, Kaushansky K, Zhan H Blood Cells Mol Dis. 2021; 90:102585.

PMID: 34139651 PMC: 8687391. DOI: 10.1016/j.bcmd.2021.102585.

References

Zhang B, Lewis S . The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol. 1989; 43(1):63-6. DOI: 10.1111/j.1600-0609.1989.tb01253.x. View

Sitnicka E, Lin N, Priestley G, Fox N, Broudy V, WOLF N . The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996; 87(12):4998-5005. View

Chute J, Saini A, Chute D, Wells M, Clark W, Harlan D . Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow. Blood. 2002; 100(13):4433-9. DOI: 10.1182/blood-2002-04-1238. View

Alexander W, Roberts A, Nicola N, Li R, Metcalf D . Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996; 87(6):2162-70. View

Zhan H, Ma Y, Lin C, Kaushansky K . JAK2-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia. 2016; 30(12):2332-2341. PMC: 5158308. DOI: 10.1038/leu.2016.114. View

Sozer S, Ishii T, Fiel M, Wang J, Wang X, Zhang W . Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009; 43(3):304-12. DOI: 10.1016/j.bcmd.2009.08.005. View

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

Nolan D, Ginsberg M, Israely E, Palikuqi B, Poulos M, James D . Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013; 26(2):204-19. PMC: 3873200. DOI: 10.1016/j.devcel.2013.06.017. View

Constien R, Forde A, Liliensiek B, Grone H, Nawroth P, Hammerling G . Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis. 2001; 30(1):36-44. DOI: 10.1002/gene.1030. View

10.

Yoder M, Mead L, Prater D, Krier T, Mroueh K, Li F . Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2006; 109(5):1801-9. PMC: 1801067. DOI: 10.1182/blood-2006-08-043471. View

11.

Sangkhae V, Etheridge S, Kaushansky K, Hitchcock I . The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood. 2014; 124(26):3956-63. PMC: 4271181. DOI: 10.1182/blood-2014-07-587238. View

12.

Li J, Kent D, Godfrey A, Manning H, Nangalia J, Aziz A . JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood. 2014; 123(20):3139-51. DOI: 10.1182/blood-2013-06-510222. View

13.

Li J, Spensberger D, Ahn J, Anand S, Beer P, Ghevaert C . JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010; 116(9):1528-38. PMC: 3145111. DOI: 10.1182/blood-2009-12-259747. View

14.

Zhang B, Ho Y, Huang Q, Maeda T, Lin A, Lee S . Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21(4):577-92. PMC: 3332001. DOI: 10.1016/j.ccr.2012.02.018. View

15.

Chute J, Muramoto G, Fung J, Oxford C . Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells. Blood. 2004; 105(2):576-83. DOI: 10.1182/blood-2004-04-1467. View

16.

Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A . Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014; 512(7512):78-81. DOI: 10.1038/nature13383. View

17.

Solar G, Kerr W, Zeigler F, Hess D, Donahue C, de Sauvage F . Role of c-mpl in early hematopoiesis. Blood. 1998; 92(1):4-10. View

18.

Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L . Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol. 2007; 140(2):162-8. DOI: 10.1111/j.1365-2141.2007.06885.x. View

19.

Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L . Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2012; 121(2):360-8. DOI: 10.1182/blood-2012-01-404889. View

20.

Mullally A, Lane S, Ball B, Megerdichian C, Okabe R, Al-Shahrour F . Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010; 17(6):584-96. PMC: 2909585. DOI: 10.1016/j.ccr.2010.05.015. View